# A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)

> **NCT02698566** · PHASE3 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 35 (actual)

## Conditions studied

- Macular Edema

## Interventions

- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT02698566
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-21
- **Primary completion:** 2016-04-05
- **Final completion:** 2016-04-05
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2017-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02698566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02698566, "A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02698566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*